>
Your Opportunity to Weigh In on Federal Vaccine Policy - Deadline Sunday Sept 20
Palantir $PLTR CEO Alex Karp says "AI companies have to be nationalized"
It's infuriating that they know better, but sell us out until they leave
World's smallest CT scanner fits in the palm of your hand
The Tesla Roadster will blow people's minds
Peter Thiel-Funded Company Anduril to Triple the Number of Autonomous Surveillance Towers...
Quantum computing may soon become part of the microscope itself.
Volkswagen Just Unveiled The Most Efficient EV Ever Tested
NASA Super Light Solar Sail Project Will Be 12-40 Times Lighter and Faster
Space Telescope Interferometer to Image Exoplanet Continents
Twenty-five years of "temporary": how 9/11 built a surveillance state Americans never vote
I'll Never Buy Another WALMART Battery!
Shoei GT-Air 3 Smart helmet drops with built-in AR for $1,500

Many patients with prostate cancer are treated with drugs to which they quickly develop resistance.
Now, a new study from Washington University School of Medicine in St. Louis has identified an RNA molecule that suppresses prostate tumors.
The scientists found that prostate cancers develop ways to shut down this RNA molecule to allow themselves to grow. However, when they implanted mice with human prostate tumor samples, the new treatment restored this so-called long noncoding RNA—and they've hailed it as a new strategy to treat the cancer which has developed resistance to hormonal therapies.